A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

NCT07006688 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

IDH1-Mutated Malignancies

Interventions

DRUG: Ivosidenib Oral Tablet

Sponsor

Servier Bio-Innovation LLC

Collaborators

[object Object]